Cardiac natriuretic hormones: methodological aspects

Immuno-Analyse et Biologie Specialisee

Volumn 22, Issue 4, 2007, Pages 236-246

  Vittorini, S ^a   Prontera, C ^a   Zucchelli, G C ^a   Clerico, A ^b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

Cardiovascular disease; Heart failure; Immunoassay

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ACCURACY; ARTICLE; CALIBRATION; CONGESTIVE HEART FAILURE; DIFFERENTIAL DIAGNOSIS; DYSPNEA; ENZYME IMMUNOASSAY; HEART LEFT VENTRICLE FAILURE; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; ISOTOPE LABELING; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

EID: 34548676369     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2007.06.003     Document Type: Article

References (98)

1. Takei Y. Does the natriuretic peptide system exsist throughout the animal and plant kingdom?. Comp. Biochem. Physiol. Part B 129 (2001) 559-573
2. de Bold A.J., Bruneau B.G., and Kuroski de Bold M.L. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc. Res. 31 (1996) 7-18
3. Goetze J.P. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin. Chem. 9 (2004) 1503-1510
4. Sumida H., Yasue H., Yoshimura M., Okumura K., Ogawa H., and Kugiyama K. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J. Am. Col. Cardiol. 25 (1995) 1105-1110
5. McGrath M.F., and de Bold A.J. Determinants of natriuretic peptides gene expression. Peptides 26 (2005) 993-994
6. Clerico A., Recchia F.A., Passino C., and Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H17-H29
7. de Lemos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 362 (2003) 316-322
8. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr. Rev. 24 (2003) 341-356
9. Zhang Q., Moalem J., Tse J., Scholz P.M., and Weiss H.R. Effects of natriuretic peptides on ventricular myocyte contraction and role of cyclic GMP signaling. Eur. J. Pharmacol. 510 (2005) 209-215
10. Nagaya N., Nishikimi T., Goto Y., Miyao Y., Kobayashi Y., Morii I., et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am. Heart J. 135 (1998) 21-28
11. Hardt S.E., and Sadoshima J. Negative regualtors of cardiac hypertrophy. Cardiovasc. Res. 63 (2004) 500-509
12. Brunner-La Rocca H.P., Kaye D.M., Woods L.R., Hastings J., and Esler M.D. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J. Am. Coll. Cardiol. 37 (2001) 1221-1227
13. Kapoun A.M., Liang F., O'Young G., Damm D.L., Quon D., White R.T., et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblast: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ. Res. 94 (2004) 453-461
14. Vollmar A.M. The role of atrial natriuretic peptide in the immune system. Peptides 26 (2005) 1086-1094
15. Clerico A., Del Ry S., and Giannessi D. Measurement of natriuretic cardiac hormones (ANP, BNP and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin. Chem. 46 (2000) 1529-1534
16. Clerico A., Del Ry S., and Giannessi D. Evaluation and comparison of commercial immunoassay methods for the determination of N-terminal proANP in plasma and atrial tissue. J. Clin. Ligand Assay 24 (2001) 112-118
17. Panteghini M., and Clerico A. Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide: the prerequisite for its optimal clinical use. Clin. Lab. (Zaragoza) 50 (2004) 325-331
18. Clerico A., and Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. Clin. Chem. 50 (2004) 33-50
19. Hammerer-Lercher A., Neubauer E., and Muller S. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin. Chim. Acta 310 (2001) 193-197
20. Prontera C., Emdin M., Zucchelli G.C., Ripoli A., Passino C., and Clerico A. Natriuretic peptides (NPs): automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. Clin. Chem. 49 (2003) 1552-1554
21. Storti S., Prontera C., Emdin M., Passino C., Prati P., Fontani G., et al. Analytical performance and clinical results of a fully automated MEIA system for BNP assay: comparison with a POCT method. Clin. Chem. Lab. Med. 42 (2004) 1178-1185
22. Wu A.H., Packer M., Smith A., Bijou R., Fink D., Mair J., et al. Analytical and clinical evaluation of the Bayer ADVIA centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin. Chem. 50 (2004) 867-873
23. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic ans asymptomatic structural heart disease. Clin. Chim. Acta 341 (2004) 41-48
24. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Biochemical diagnosis of impaired left ventricular ejection fraction - comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP). Clin. Chem. Lab. Med. 42 (2004) 159-163
25. Hammerer-Lercher A., Ludwig W., Falkensammer G., Muller S., Neubauer E., Pushendorf B., et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin. Chem. 50 (2004) 1174-1183
26. Yandle T.G., Espiner E.A., Nicholls M.G., and Duff H. Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J. Clin. Endocrinol. Metab. 63 (1986) 72-79
27. Hartter E., Woloszczuk W., and Stummvoll H.K. Radioimmunoassay of atrial natriuretic peptide in human plasma. Clin. Chem. 32 (1986) 441-445
28. Clerico A., Del Chicca M.G., Zucchelli G.C., Giganti M., and Piffanelli A. Evaluationa nd comparison of the analytical performances of two RIA kits for the assay of atrial natriuretic peptide (ANP). J. Nucl. Med. All Sci. 34 (1990) 81-87
29. Clerico A., Giuseppe O., Pelizzola D., et al. Evaluation of the clinical performance of RIA methods for measurement of ANP. J. Clin. immunoassay 14 (1991) 251-256
30. Richards A.M., Tomolo G., McIntyre G.D., Leckie B.J., and Robertson J.L. Radio-immunoassay for plasma alpha human atrial natriuretic peptide; a comparison of direct and preextracted methods. J. Hypertens. 5 (1987) 227-236
31. Lewis H.M., Ratcliffe W.A., Stott R.A.W., Wilkins M.R., and Baylis P.H. Development and validation of a two-site immunoradiometric assay for human atrial natriuretic factore in unextracted plasma. Clin. Chem. 35 (1989) 953-957
32. Tattersal J.E., Daenay A., McLean C., and Cattel W.R. Immunoradiometric assay of atrial natriuretic peptide in unextracted plasma. Clin. Chem. 36 (1990) 855-859
33. Clerico A., Iervasi G., Del Chicca M.G., Maffei S., Berti S., Sabatino L., et al. Analytical performance and clinical usefulness of a commercially available IRMA kit for the measurement of atrial natriuretic peptide in patients with heart failure. Clin. Chem. 42 (1996) 1627-1633
34. Tsuji T., Masuda H., Imagawa, Haraikawa M., Shibata K., Kono M., et al. Stability of human atrial natriuretic peptide in blood samples. Clin. Chim. Acta 225 (1994) 171-177
35. Itoh H., Nakao K., Sugawara, Saito Y., Mukoyama M., Morii N., et al. Gamma-atrial natriuretic polypeptide (gamma ANP)-derived peptides in human plasma: cosecretion of N-terminal gamma-ANP fragment and alpha-ANP. J. Clin. Endocrinol. Metab. 67 (1988) 429-437
36. Sundsfiord J.A., Thibault G., Larochelle P., and Cantin M. Identification and plasma concentration of the N-terminalfragment of atrial natriuretic factor in man. J. Clin. Endocrinol. Metab. 66 (1988) 605-610
37. Buckley M.G., Markandu N.D., Sagnella G.A., and MacGregor G.A. N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassay for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126). Clin. Sci. 87 (1994) 311-317
38. Mathisen P., Hall C., and Simonsen S. Comparative study of atrial peptides ANF(1-98) and ANF(99-126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand. J. Clin. Lab. Invest. 53 (1993) 41-49
39. Winters C.J., Sallman A.L., Baker B.J., Meadows J., Rico D.M., and Vesely D.L. The N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 80 (1989) 438-449
40. Vesely D.L., Douglass M.A., Dietz J.R., Gower Jr. W.R., McCormick M.T., and Rodriguez-Paz G. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 90 (1994) 1129-1140
41. Overton R.M., and Vesely D.L. Processing of long-acting natriuretic peptide and vessel dilator in human plasma and serum. Peptides 17 (1996) 1155-1162
42. Vesely D.L. Natriuretic peptides and acute renal failure. Am. J. Physiol. Renal Physiol. 285 (2003) F167-F177
43. Numata Y., Dohi K., Furukawa A., Kikuoka S., Asada H., Fukunaga T., et al. Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma. Clin. Chem. 44 (1998) 1008-1013
44. Togashi K., Hirata Y., Ando K., Takey Y., Kawakami M., and Marumo F. Brain natriuretic peptide-like immunoreactivity is present in human plasma. FEBS Lett. 250 (1989) 235-237
45. Lang C.C., Coutie W.J., Khong T.K., Choy A.M., and Struthers A.D. Dietary sodium loading increases plasma brain natriuretic peptide levels in man. J. Hyperthens 9 (1991) 779-782
46. Hasegawa K., Fujiwara H., Doyama K., Miyamae M., Fujiwara T., Suga S., et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 88 (1993) 372-380
47. Yandle T.G., Richards A.M., Gilbert A., Fisher S., Holmes S., and Espiner E.A. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J. Clin. Endocrinol. Metab. 76 (1993) 832-838
48. Kono M., Yamauchi A., Tsuji T., et al. An immunoradiometric assay for brain natriuretic peptide in human plasma. Kaku Igaky 13 (1993) 2-7
49. Del Ry S., Clerico A., Giannessi D., Andreassi M.G., Caprioli R., Iascone M.R., et al. Measurement of brain natriuretic peptide in plasma samples and cardiac tissue extracts by means of an IRMA method. Scand. J. Clin. Lab. Invest. 60 (2000) 81-90
50. Clerico A., Iervasi G., Del Chicca M.G., Emdin M., Maffei S., Nannipieri M., et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J. Endocrinol. Invest. 21 (1998) 170-178
51. Del Ry S., Giannessi D., and Clerico A. Plasma brain natriuretic peptide measured by fully-automated immunoassay and by immunoradiometric assay compared. Clin. Chem. Lab. Med. 39 (2001) 446-450
52. Fisher Y., Filzmaier K., Stiegler H., Graf J., Fuhs S., Franke A., et al. Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic peptide. Clin. Chem. 47 (2001) 591-594
53. Vogeser m, Jacob C. B-type natriuretic peptide (BNP) - validation of an immediate response assay. Clin. Lab. (Zaragoza) 47 (2001) 29-33
54. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Preliminary evaluation of the AxSYM B-type natriuretic peptide (BNP) assay and comparison with the ADVIA Centaur BNP assay. Clin. Chem. 50 (2004) 1104-1106
55. Clerico A., Prontera T., Emdin M., Passino C., Storti S., Zyw L., et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin. Chem. 51 (2005) 445-447
56. Prontera C., Storti S., Emdin M., Passino C., Zyw L., Zucchelli G.C., et al. comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic peptide. Clin. Chem. 51 (2005) 1274-1276
57. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Comparison of the Biomedica NT-pro-BNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin. Chem. 49 (2003) 976-979
58. Yeo K.T.J., Wu A.H.B., Apple F.S., Kroll M.H., Christensn R.H., Lawandrowski K.B., et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin. Chim. Acta 388 (2003) 107-115
59. Prontera T., Emdin M., Zucchelli G.C., Ripoli A., Passino C., and Clerico A. Natriuretic peptides (NPs): automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. Clin. Chem. 49 (2003) 1552-1554
60. Barnes S.C., Collinson P.O., Galasko G., Lahiri A., and Senior R. Evaluation of N-terminal pro-B type natriuretic peptide analysis on the Elacsys 1010 and 2010 Analysers. Ann. Clin. Biochem. 41 (2004) 459-463
61. Sokoll L.J., Baum H., Collinson P.O., Gurr E., Haass M., Luthe H., et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin. Chem. Lab. Med. 42 (2004) 965-972
62. Goetze J.P. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin. Chem. 50 (2004) 1503-1510
63. Shimizu H., Masuta K., Asada H., Sugita K., and Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin. Chim. Acta 334 (2003) 233-239
64. Hunt P.J., Espiner E.A., Nicholls M.G., Richards A.M., and Yandle T.G. The role of circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32. Peptides 18 (1997) 1475-1481
65. Seidler T., Pemberton C., Yandle T., Espiner E., Nicholls M.G., and Richards A.M. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Iochem. Biophys. Res. Commun. 255 (1999) 495-501
66. Crimmins D.L. Human N-terminal proBNP is a monomer. Clin. Chem. 51 (2005) 1035-1038
67. Shimizu H., Aono K., Masuta K., Asada H., Misaki A., and Teraoka H. Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system. Clin. Chim. Acta 305 (2001) 181-186
68. Belenky A., Smith A., Zhang B., Lin S., Despres N., Wu A.H., et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin. Chim. Acta 340 (2004) 163-172
69. Brandt I., Lambeir A.M., Ketelslegers J.M., Vanderheyden M., Scharpe S., and De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin. Chem. 52 (2006) 82-87
70. Ala-Kopsala M., Magga J., Peuhkurinen K., Leipala J., Ruskoaho H., Leppaluoto J., et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin. Chem. 50 (2004) 1576-1588
71. Rawlins M.L., Owen W.E., and Roberts W.L. Performance characteristics of four automated natriuretic peptide assays. Am. J. Clin. Pathol. 123 (2005) 439-445
72. Goetze J.P., Kastrup J., Pedersen F., and Rehfeld J.F. Quantification of pro-B-type natriuretic peptide and ist products in human plasma by use of an analysis independent of precursor processing. Clin. Chem. 48 (2002) 1035-1042
73. Giuliani I., Rieunier F., Larue C., Delagneau J.F., Granier C., Pau B., et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin. Chem. 52 (2006) 1054-1061
74. Apple F.S., Panteghini M., Ravkilde J., Mair J., Wu A.H., Tate J., et al. Quality specification for B-type natriuretic peptide assays. Clin. Chem. 51 (2005) 486-493
75. Smith A.C., and Wu A.H. Analytical performance evaluation of the Bayer Advia Centaur BNP immunoassay. Clin. Chem. 49 suppl (2003) A71
76. Collinson P.O., Barnes S.C., Gaze D.C., Galasko G., Lahiri A., and Senior L. Analytical performance of the N-terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur. J. Heart Fail. 6 (2004) 365-368
77. Shimizu H., Aono K., Masuta K., Asada H., Misaki A., and Teraoka H. Stability of brain natriuretic peptide (BNP) in human blood samples. Clin. Chim. Acta 285 (1999) 169-172
78. Del Ry S., Maltinti M., Emdin M., Passino C., Catalano G., and Giannessi D. Radioimmunoassay for plasma C-type natriuretic peptide determination: a methodological evaluation. Clin. Chem. Lab. Med. 43 (2005) 641-645
79. Piao F.L., Park S.H., Han J.H., Cao C., Kim S.Z., and Kim S.H. Dendroaspis natriuretic peptide and its functions in pig ovarian granulose cells. Regul. Pept. 118 (2004) 193-198
80. Cartens J., Jensen K.T., Ivarsen P., Rasmussen L.M., and Pedersen E.B. Development of a urodilatin specific antibody and radioimmunoassay for urodilatin in human urine. Clin. Chem. 43 (1997) 638-643
81. Shulz-Knappe P., Forssmann K., Hock D., Herbst F., Pipkom R., and Forssmann W.G. Isolation and structural analysis of "urodilatin", a new peptide of cardiodilatin -(ANP)-family, extracted from human urine. Klin. Wochenschr. 66 (1988) 752-759
82. Schweitz H., Vigne P., Moinier D., Frelin C., and Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J. Biol. Chem. 267 (1992) 13928-13932
83. Richards A.M., Lainchbury J.G., Nicholls M.G., Cameron A.V., and Yandle T.G. Dendroaspis natriuretic peptide: endogenous or dubious?. Lancet 359 (2002) 5-6
84. Del Ry S., Passino C., Emdin M., and Giannessi D. C-type natriuretic peptide and heart failure. Pharmacol. Res. 54 (2006) 326-333
85. Barr C.S., Rhodes P., and Struthers A.D. C-type natriuretic peptide. Peptides 17 (1996) 1243-1251
86. Chen H.H. Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J. Cardiovasc. Pharmacol. 32 suppl 3 (1998) S22-S28
87. Kalra P.R., Anker S.D., Struthers A.D., and Coats A.J.S. The role of C-type natruretic peptide in cardiovascular medicine. Eur. Heart J. 22 (2001) 997-1007
88. Prickett T.C.R., Yandle T.G., Nicholls M.G., Espiner E.A., and Richards A.M. Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochem. Biophys. Res. Commun. 286 (2001) 513-517
89. Ahluwalia A., and Hobbs A.J. Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarized factor. Trends Pharmacol. Sci. 26 (2005) 162-167
90. Scotland R.S., Ahluwalia A., and Hobbs A.J. C-type natriuretic peptide in vascular physiology and disease. Pharmacol. Ther. 105 (2005) 85-93
91. Takeuchi H., Ohmori K., Kondo I., Oshita A., Shinomiya K., Takagi Y., et al. Potentiation of C-type natriuretic peptide with ultrasound and microbubbles to prevent neointimal formation after vascular injury in rats. Cardiovasc. Res. 58 (2003) 231-238
92. Wei C.M., Heublein D.M., Perrella M.A., Lerman A., Rodeheffer R.J., and Mc Gregor C.G. Natriuretic peptide system in human heart failure. Circulation 88 (1993) 1004-1009
93. Totsune K., Takahashi K., Murakami O., Satoh F., Sone M., and Mouri T. Elevated plasma C-type natriuretic peptide concentrations in patients with chronic renal failure. Clin. Sci. 87 (1994) 319-322
94. Cargill R.I., Barr C.S., Coutie W.J., Struthers A.D., and Lipworth B.J. C-type natriuretic peptide levels in cor pulmonale and in congestive heart failure. Thorax 49 (1994) 1247-1249
95. Gulberg V., Moller S., Henriksen J.H., and Gerbes A.L. Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure. Gut 47 (2000) 852-857
96. Del Ry S., Passino C., Maltinti M., Emdin M., and Giannessi D. C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severità. Eur. J. Heart Fail. 7 (2005) 1145-1148
97. The Task Force on Acute Heart Failure of the European Society of Cardiology. Guidelines on the diagnosis and treatment of acute heart failure: full text. Eur. Soc. Cardiol. 2005, 1-36.
98. The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text. European Society of Cardiology (2005) 1-45